Cargando…

Cervical cancer screening at a tertiary care center in Rwanda

In limited resource settings such as Rwanda, visual inspection with acetic acid (VIA) is the primary model for cervical cancer screening. The objective of this study was to describe clinical characteristics and outcomes for women presenting for cervical cancer screening. A prospective, observational...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruzigana, George, Bazzet-Matabele, Lisa, Rulisa, Stephen, Martin, Allison N., Ghebre, Rahel G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458073/
https://www.ncbi.nlm.nih.gov/pubmed/28616457
http://dx.doi.org/10.1016/j.gore.2017.05.005
_version_ 1783241678233010176
author Ruzigana, George
Bazzet-Matabele, Lisa
Rulisa, Stephen
Martin, Allison N.
Ghebre, Rahel G.
author_facet Ruzigana, George
Bazzet-Matabele, Lisa
Rulisa, Stephen
Martin, Allison N.
Ghebre, Rahel G.
author_sort Ruzigana, George
collection PubMed
description In limited resource settings such as Rwanda, visual inspection with acetic acid (VIA) is the primary model for cervical cancer screening. The objective of this study was to describe clinical characteristics and outcomes for women presenting for cervical cancer screening. A prospective, observational study was conducted between September 2015 and February 2016 at Kigali University Teaching Hospital (CHUK). Women referred to the VIA clinic were enrolled and completed a semi-structured questionnaire. During the six-month study period, 150 women were enrolled and evaluated with VIA followed by colposcopy directed biopsy for VIA positive. The median age was 42 years (IQR 36–49). Only 20 (13.3%) asymptomatic women presented for screening exam, whereas 126 (84%) were symptomatic. Among symptomatic patients, more than one-third had never had a speculum exam prior to referral (n = 43). Twenty-two (14.7%) women were VIA positive, and 8 (5.3%) had lesions suspicious for cancer, while 120 (80%) were found to be VIA negative. Among women undergoing biopsy (n = 30), 11 were normal (36.7%), 5 cases showed CIN 1 (16.6%), 4 cases showed CIN 2 (13.3%), 2 cases showed CIN 3 (6.7%) and 8 were confirmed cervical cancers (26.7%). In Rwanda, VIA is the current method for cervical cancer screening. In this study, few asymptomatic patients presented for cervical cancer screening. Increasing knowledge about cervical cancer screening and expanding access are key elements to improving cervical cancer control in Rwanda.
format Online
Article
Text
id pubmed-5458073
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-54580732017-06-14 Cervical cancer screening at a tertiary care center in Rwanda Ruzigana, George Bazzet-Matabele, Lisa Rulisa, Stephen Martin, Allison N. Ghebre, Rahel G. Gynecol Oncol Rep Survey Article In limited resource settings such as Rwanda, visual inspection with acetic acid (VIA) is the primary model for cervical cancer screening. The objective of this study was to describe clinical characteristics and outcomes for women presenting for cervical cancer screening. A prospective, observational study was conducted between September 2015 and February 2016 at Kigali University Teaching Hospital (CHUK). Women referred to the VIA clinic were enrolled and completed a semi-structured questionnaire. During the six-month study period, 150 women were enrolled and evaluated with VIA followed by colposcopy directed biopsy for VIA positive. The median age was 42 years (IQR 36–49). Only 20 (13.3%) asymptomatic women presented for screening exam, whereas 126 (84%) were symptomatic. Among symptomatic patients, more than one-third had never had a speculum exam prior to referral (n = 43). Twenty-two (14.7%) women were VIA positive, and 8 (5.3%) had lesions suspicious for cancer, while 120 (80%) were found to be VIA negative. Among women undergoing biopsy (n = 30), 11 were normal (36.7%), 5 cases showed CIN 1 (16.6%), 4 cases showed CIN 2 (13.3%), 2 cases showed CIN 3 (6.7%) and 8 were confirmed cervical cancers (26.7%). In Rwanda, VIA is the current method for cervical cancer screening. In this study, few asymptomatic patients presented for cervical cancer screening. Increasing knowledge about cervical cancer screening and expanding access are key elements to improving cervical cancer control in Rwanda. Elsevier 2017-05-26 /pmc/articles/PMC5458073/ /pubmed/28616457 http://dx.doi.org/10.1016/j.gore.2017.05.005 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Survey Article
Ruzigana, George
Bazzet-Matabele, Lisa
Rulisa, Stephen
Martin, Allison N.
Ghebre, Rahel G.
Cervical cancer screening at a tertiary care center in Rwanda
title Cervical cancer screening at a tertiary care center in Rwanda
title_full Cervical cancer screening at a tertiary care center in Rwanda
title_fullStr Cervical cancer screening at a tertiary care center in Rwanda
title_full_unstemmed Cervical cancer screening at a tertiary care center in Rwanda
title_short Cervical cancer screening at a tertiary care center in Rwanda
title_sort cervical cancer screening at a tertiary care center in rwanda
topic Survey Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458073/
https://www.ncbi.nlm.nih.gov/pubmed/28616457
http://dx.doi.org/10.1016/j.gore.2017.05.005
work_keys_str_mv AT ruziganageorge cervicalcancerscreeningatatertiarycarecenterinrwanda
AT bazzetmatabelelisa cervicalcancerscreeningatatertiarycarecenterinrwanda
AT rulisastephen cervicalcancerscreeningatatertiarycarecenterinrwanda
AT martinallisonn cervicalcancerscreeningatatertiarycarecenterinrwanda
AT ghebrerahelg cervicalcancerscreeningatatertiarycarecenterinrwanda